Analysts Anticipate IMV Inc. (NASDAQ:IMV) to Post -$0.18 Earnings Per Share

Wall Street brokerages forecast that IMV Inc. (NASDAQ:IMV – Get Rating) will announce earnings of ($0.18) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for IMV’s earnings. IMV posted earnings per share of ($0.10) in the same quarter last year, which indicates a negative year-over-year growth rate of 80%. The business is expected to issue its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that IMV will report full year earnings of ($0.47) per share for the current year, with EPS estimates ranging from ($0.71) to ($0.28). For the next financial year, analysts expect that the company will report earnings of ($0.42) per share, with EPS estimates ranging from ($0.55) to ($0.28). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow IMV.

IMV (NASDAQ:IMV – Get Rating) last announced its earnings results on Thursday, March 17th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.01). IMV had a negative return on equity of 145.26% and a negative net margin of 19,535.29%. During the same quarter last year, the company earned ($0.11) EPS.

Several brokerages have recently weighed in on IMV. Zacks Investment Research cut shares of IMV from a “hold” rating to a “sell” rating in a research note on Tuesday, March 22nd. Raymond James decreased their target price on shares of IMV from $1.75 to $1.50 and set a “market perform” rating for the company in a research note on Friday, March 18th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $2.22.

IMV stock remained flat at $$1.36 during mid-day trading on Wednesday. 5,001 shares of the company’s stock traded hands, compared to its average volume of 128,729. The company has a current ratio of 5.01, a quick ratio of 5.01 and a debt-to-equity ratio of 0.90. The company has a market cap of $111.82 million, a price-to-earnings ratio of -2.85 and a beta of 1.32. The business has a fifty day simple moving average of $1.30 and a 200 day simple moving average of $1.41. IMV has a 52-week low of $1.05 and a 52-week high of $2.96.

Hedge funds have recently bought and sold shares of the stock. Hartford Financial Management Inc. raised its stake in IMV by 45.2% during the third quarter. Hartford Financial Management Inc. now owns 64,463 shares of the company’s stock worth $107,000 after acquiring an additional 20,063 shares in the last quarter. First City Capital Management Inc. raised its stake in IMV by 119.0% during the third quarter. First City Capital Management Inc. now owns 496,421 shares of the company’s stock worth $824,000 after acquiring an additional 269,720 shares in the last quarter. LexAurum Advisors LLC raised its stake in IMV by 69.5% during the fourth quarter. LexAurum Advisors LLC now owns 164,570 shares of the company’s stock worth $201,000 after acquiring an additional 67,500 shares in the last quarter. Susquehanna International Group LLP raised its stake in IMV by 50.6% during the fourth quarter. Susquehanna International Group LLP now owns 205,492 shares of the company’s stock worth $251,000 after acquiring an additional 69,029 shares in the last quarter. Finally, Morgan Stanley raised its stake in IMV by 13,722.0% during the second quarter. Morgan Stanley now owns 41,466 shares of the company’s stock worth $91,000 after acquiring an additional 41,166 shares in the last quarter. 13.05% of the stock is owned by institutional investors and hedge funds.

About IMV (Get Rating)

IMV, Inc is a clinical-stage biopharmaceutical company that engages in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company leverages its delivery platform (DPX) that programs immune cells directly within the human body to produce robust and sustained target killing capabilities.

Featured Stories